A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Latest Information Update: 02 Mar 2021
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Registrational; Therapeutic Use
- Acronyms ELARIS EM-II; ELARIS-II; EM-II; Solstice
- Sponsors AbbVie; AbbVie Germany
- 06 Aug 2020 Results (n=1686) of pooled analysis of two studies (ELARIS I and II) assessing health-related quality of life measured by EP-30, published in the Obstetrics and Gynecology.
- 20 May 2020 Results of post hoc pooled analysis of ELARIS I and II trial quantifying changes in health-related quality of life (HRQOL) among patients with endometriosis who experience a clinically meaningful reduction in dyspareunia presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 12 Nov 2019 Results of post hoc analysis utilized data from two phase III, randomized, double-blind, placebo-controlled clinical studies (EM-I and EM-II) which evaluated the efficacy of elagolix among women with moderate-to-severe endometriosis-related painpublished in the American Journal of Obstetrics and Gynecology